Genome Editing Scientist - TGEn Lab (Sickle Cell)

St. Jude Children's Research Hospital; Memphis, Northern (TN, KY); Hybrid; USD 66,000 - 114,000; Full time

Job summary

St. Jude Children’s Research Hospital in Memphis, TN seeks an Associate Scientist or Scientist to join the Yen Lab/TGEn Group. You will work on genome editing strategies for sickle cell disease, collaborating with a multidisciplinary team to translate discoveries to a Phase 1 clinical trial.

The role offers opportunities to develop pre-clinical genome editing strategies, process development, and IND-enabling studies, with a focus on lipid nanoparticle delivery and cellular therapies.

Qualifications

• Bachelor’s degree in a relevant scientific area is required.
• Master’s or PhD degree in a relevant scientific area is highly preferred.

Responsibilities

• Perform studies to develop genome editing strategies for human hematopoietic stem cells (HSC).
• Design and execute IND-enabling experiments to characterize pharmacology of genome-edited HSC products.
• Characterize efficacy, safety, and potency of the HSC product in vitro and in xenotransplantation assays.
• Multicolor flow cytometry and FACS to sort hematopoietic populations of relevance.
• Develop methods including RT-PCR, ddPCR, NGS, and single-cell sequencing.
• Perform NGS library preparation and analysis of editing outcomes, on-target and off-target.
• Evaluate scale-up and close-system processes to ensure reproducibility of the drug product.
• Interact with multidisciplinary teams to advance the program.
• Draft documentation (protocols, batch records, reports) to standardize transfer to GMP.

Education

Bachelor’s degree in a relevant scientific area

Master’s or PhD degree in a relevant scientific area

Job description

St. Jude Children’s Research Hospital in Memphis, TN seeks an Associate Scientist or Scientist to join the Yen Lab/TGEn Group. You will work on genome editing strategies for sickle cell disease, collaborating with a multidisciplinary team to translate discoveries to a Phase 1 clinical trial.

The role offers opportunities to develop pre-clinical genome editing strategies, process development, and IND-enabling studies, with a focus on lipid nanoparticle delivery and cellular therapies.